Mario Aguilar

By Mario Aguilar April 1, 2024 T he Food and Drug Administration has cleared Otsuka Pharmaceutical's digital treatment for major depressive

In this edition of the Health Tech newsletter, we talk to investor Glen Tullman about his new $100 million fund, and other things health tech.

By Mario Aguilar April 5, 2024 I n a decision that surprised Wall Street analysts, Teladoc Health announced that long-time CEO Jason Gorevic will depart the company immediately.

Gorevic's departure follows a series of missed financial projections, a precipitous decline in Teladoc’s stock price, and an uninspired vision for its future.

As sales slump, the prescription digital therapeutics maker lays off 46% of workforce, and will "evaluate potential strategic alternatives."

The new funding led by General Catalyst and 7wireVentures values Transcarent at $2.2 billion, will be used for AI projects, acquisitions.

W ASHINGTON — Members of Congress appear poised to advance another short-term extension of pandemic-era telehealth flexibilities instead of permanently addressing the issue, seven sources familiar with the talks said.

A House proposal includes extension of more flexible rules for telehealth and hospital home-care programs. To pay for it, it seeks new limits on pharmacy benefit managers.

The FDA nod means trial sponsors can use Apple Watch's A-fib history as a secondary endpoint in trials without having to do additional work.

By Katherine MacPhail and Mario Aguilar May 16, 2024 S AN FRANCISCO — In the world of drug discovery, AI progress is often measured by a single-mile marker: When will we get an AI-designed drug?